Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors

• Status: Completed
• Trial end date: 2017-07-10
• Target enrollment: 0
• Participant gender: Female

Summary

Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fundació Privada Eugin
• Treatments: Ganirelix

Criteria

Inclusion Criteria:

• Oocyte donors included in the oocyte donation program of Clinica EUGIN.

• 1st oocyte donation cycle at Clínica EUGIN.

Exclusion Criteria:

• Polycistic Ovarian syndrome (PCOs).

• Estradiol levels on day 2 of menstrual cycle >70 pg/ml.

• Hormone treatments up to 3 months before the oocyte donation cycle.

• Medical contraindication to the treatments used in the study